Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01160289 · ClinicalTrials.gov registry record · Phase 2
A Study of LY900010 in Erectile Dysfunction
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 410
- Enrollment target
NCT01160289 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 410 participants.
The verdict
NCT01160289, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 410 participants
- Enrollment target
Study Summary
The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone.
Interventions
- DRUG tadalafil
- DRUG LY2452473
- DRUG placebo (tadalafil)
- DRUG placebo (LY2452473)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 410 participants |
| Start Date | 2010-10 |
| Est. Completion | 2011-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01160289
The ClinicalTrials.gov registry entry for NCT01160289 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 410 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which tadalafil is the first listed.
NCT01160289 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01160289 about?
NCT01160289 is a clinical study titled "A Study of LY900010 in Erectile Dysfunction". The primary purpose of the study is to compare the efficacy of LY2452473 + tadalafil to tadalafil alone in improving the erectile function (EF) of men with erectile dysfunction (ED) who incompletely respond to tadalafil alone.
What is the current status of trial NCT01160289?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 410 participants. The study started on 2010-10. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01160289?
The interventions under investigation include: tadalafil (DRUG), LY2452473 (DRUG), placebo (tadalafil) (DRUG), placebo (LY2452473) (DRUG).
Who is sponsoring clinical trial NCT01160289?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.